CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 345 enrolled
Drug / intervention
Placebo +5 moredrug
Likely dose
PF-04937319 - 3mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01475461
NCT01475461Phase 2Completed
CompareCT.gov

A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose-ranging, Parallel Group Study To Evaluate Safety And Efficacy Of Pf-04937319 And Sitagliptin On Glycemic Control In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin

Pfizer·interventional·Posted Nov 21, 2011·Updated Jan 31, 2017

In Brief

A Phase 2 clinical trial evaluating Placebo, PF-04937319 - 3mg, and 4 other interventions for Type 2 Diabetes Mellitus. Completed, enrolled 345 participants across 63 sites in 8 countries.

Detailed Summary

B1621007 is designed to study the safety and efficacy of PF-04937319 in patients with type 2 diabetes

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesHungary, India, Philippines, Romania, Slovakia, South Africa, Taiwan, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 21, 2011
Enrollment StartNov 1, 2011
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 14.6 years ago

Interventions

Placebodrug

double-dummy placebo tablets administered once-daily for 84-days

PF-04937319 - 3mgdrug

PF-04937319 3mg administered as tablets once-daily for 84-days

PF-04937319 - 20mgdrug

PF-04937319 20mg administered as tablets once-daily for 84-days

PF-04937319 - 50mgdrug

PF-04937319 50mg administered as tablets once-daily for 84-days

PF-04937319 - 100mgdrug

PF-04937319 100mg administered as tablets once-daily for 84-days

Sitagliptin - 100mgdrug

Sitagliptin 100mg administered as tablets once-daily for 84-days